1398695-47-0

1398695-47-0 structure

Name: GSK2646264
Chemical Name: GSK2646264
CAS Number: 1398695-47-0
Molecular Formula: C₂₄H₂₆N₂O₂
Molecular Weight: 374.48
Catalog: Signaling Pathways Autophagy LRRK2
Create Date: 2022-03-28 13:13:40
Modify Date: 2024-01-02 12:36:56
GSK2646264 (Compound 44) is a potent and selective spleen tyrosine kinase (SYK) inhibitor with a pIC50 of 7.1. GSK2646264 also inhibits other kinases with pIC50 values of 5.4, 5.4, 5.3, 5, 4.5, <4.6 and <4.3 against LCK, LRRK2, GSK3β, JAK2, VEGFR2, Aurora B and Aurora A, respectively. GSK2646264 is penetrable into the epidermis and dermis of the skin[1].

Name	GSK2646264
Synonyms	7-{2-Methoxy-6-[(4-methyl-2-pyridinyl)methoxy]phenyl}-2,3,4,5-tetrahydro-1H-3-benzazepine 1H-3-Benzazepine, 2,3,4,5-tetrahydro-7-[2-methoxy-6-[(4-methyl-2-pyridinyl)methoxy]phenyl]-

Description	GSK2646264 (Compound 44) is a potent and selective spleen tyrosine kinase (SYK) inhibitor with a pIC50 of 7.1. GSK2646264 also inhibits other kinases with pIC50 values of 5.4, 5.4, 5.3, 5, 4.5, <4.6 and <4.3 against LCK, LRRK2, GSK3β, JAK2, VEGFR2, Aurora B and Aurora A, respectively. GSK2646264 is penetrable into the epidermis and dermis of the skin[1].
Related Catalog	Signaling Pathways >> Epigenetics >> Aurora Kinase Signaling Pathways >> Stem Cell/Wnt >> GSK-3 Signaling Pathways >> Cell Cycle/DNA Damage >> Aurora Kinase Signaling Pathways >> JAK/STAT Signaling >> JAK Signaling Pathways >> Epigenetics >> JAK Signaling Pathways >> Stem Cell/Wnt >> JAK Signaling Pathways >> Protein Tyrosine Kinase/RTK >> Src Signaling Pathways >> Autophagy >> LRRK2 Signaling Pathways >> Protein Tyrosine Kinase/RTK >> Syk Research Areas >> Inflammation/Immunology Signaling Pathways >> Protein Tyrosine Kinase/RTK >> VEGFR Signaling Pathways >> PI3K/Akt/mTOR >> GSK-3
Target	SYK:7.1 (pIC50) LCK:5.4 (pIC50) LRRK2:5.4 (pIC50) GSK3β:5.3 (pIC50) JAK2:5 (pIC50) VEGFR2:4.5 (pIC50) Aurora B:<4.6 (pIC50) Aurora A:<4.3 (pIC50)
References	[1]. Barker MD, et al. Discovery of potent and selective Spleen Tyrosine Kinase inhibitors for the topical treatment of inflammatory skin disease. Bioorg Med Chem Lett. 2018 Nov 15;28(21):3458-3462.